Ballicules.com

Rimegepant

NURTEC

What it isCGRP-receptor antagonist; acute treatment and prevention of migraine.

Why this oneIt serves both acute and preventive roles and, unlike triptans, does not cause vasoconstriction.

What limits itStrong CYP3A4 inhibitors must be avoided; cost and prior authorization frequently block access.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Acute treatment of migraineadult75 mg PRN75 mg PRN75 mg/24 h
Preventive treatment of episodic migraineadult75 mg every other day75 mg every other day75 mg every other day

Renal Mild-moderate-severe: no adjustment; avoid in ESRD (CrCl <15)

Hepatic Mild-moderate (Child-Pugh A/B): no adjustment; avoid in severe (Child-Pugh C)

Acute: max 75 mg/24 h; safety of >18 doses per 30 days not established. Avoid another dose within 48 h of a moderate CYP3A4 inhibitor or potent P-gp inhibitor

Instructions

Cautions

Adverse reactions

Pregnancy No adequate human data; animal effects (decreased fetal weight, skeletal variations) at high maternally toxic doses

Lactation Low transfer into breast milk (relative infant dose <1%)

NO BOXED WARNINGS

Principal riskLittle; CYP3A4-dependent

Cost, est. cash$500–$1,200/month

Generic entry2039 est.

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryNot assigned — PLLR-era drug

Defining liabilityAgent-specific vascular, serotonergic or hepatic risks; acute overdose is usually limited outside ergot or cardiovascular agents.

Mechanism of action: Rimegepant ballicule

Rimegepant ballicule: receptor binding, kinetics and half-life diagram

Open Rimegepant in the interactive console ↗

Memory aids: mascots and interaction avatars

Rimegepant NURTEC ODT mascot mnemonic cartoon
“Rhymin’ G pants are Nerd tech?”
Rimegepant CYP3A4 substrate avatar
CYP3A4 substrate

Open Rimegepant in the interactive console ↗